MetaVia Inc. — Director's Dealing 2018

Feb 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2018-02-08

Reporting Person: Gullans Steven R. Ph.D. (Director, Interim President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-08	Common Stock	P	71429	$7	Acquired	930252	Indirect

Footnotes

F1: The shares were purchased in a confidentially marketed public offering pursuant to an Underwriting Agreement. The offering closed on February 12, 2018.

F2: The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.